Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-60.0,  Type 2 Diabetes Men from 40 to 65 years old. (excluding women because of hormonal changes in post menopause period could be influenced lipid parameters) Type 2 diabetes as defined by the American Diabetes Association Body mass index between 25 and 40.0 kg/m² Baseline glycated hemoglobin A1c (HbA1c) between 7 and 10 % Patients having received stable doses of metformin for at least 3 months before randomization Non-smoker Subject without cardiovascular events 6 months ago. (the treatment with lipid lowering agents and beta blockers in this condition could be perturbed the lipids parameters) Subject is informed and is consented Plasma without severe dyslipidaemia: plasma triglyceride levels <4.51mmol/L (<400 mg/dl), plasma HDL levels >1.0 mmol/L (>40 mg/dl), LDL-cholesterol <5.10 mmol/L (<200 mg/dl)  Patients having received or being treated with pioglitazone, GLP-1 analogues, insulin or anti-obesity drugs (orlistat) within the past 3 months will be excluded Patients taking any other hypoglycemic agent, other than metformin Patients with type 1 diabetes, secondary diabetes or acute metabolic diabetic complications will be excluded Subjects will be excluded if they have cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents: (statins, fibrates, ezetimibe, niacin), significant alcohol intake etc.) Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study Individuals with a history of mental instability, individuals who have been treated or are being treated for severe psychiatric illness that, in the opinion of the investigator, may interfere with optimal participation in the study History of alcohol or drug abuse within the past 2 years. Patients must not take alcohol during the study Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease, that would limit study evaluation or participation Known impairment of renal function (serum creatinine levels > 1.7 mg/dL for men), dysproteinemia, nephrotic syndrome, or other renal disease (24-hour urinary protein ≥3 ± 1 g) Active or chronic hepatobiliary or hepatic disease. In addition, patients with aspartate aminotransferase or alanine aminotransferase >2 x upper limit of the laboratory reference range will be excluded